Clinical MilestonesThe initiation of ALG-000184's randomized, double-blind, active-controlled Phase 2 study is regarded as Aligos' next major milestone.
Market DifferentiationALG-000184 achieved the primary endpoint in 100% of patients in the Phase 1 study, compared to 21% for the standard-of-care treatment.
Therapeutic PotentialALG-000184 showcased robust and sustained antiviral activity in both HBeAg-positive and HBeAg-negative patients with CHB, highlighting its potential as a first-line therapy for long-term viral suppression.